Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)

NCT02740972 is registered in ClinicalTrials.gov with NS Pharma, Inc. as lead sponsor.

NCT NCT02740972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02740972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Lead sponsor
NS Pharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2016
Completion date
April 30, 2018
Enrollment
16 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy